World Health Organization Raises Alert Over Acute Scarcity of Obesity Jabs
Less than a tenth of people who could benefit from GLP-1 drugs including Wegovy are able to get them, warns the World Health Organization as it releases its first advice on the therapies.
With in excess of 1,000,000,000 individuals worldwide currently obese, it is advocating for broader and more equitable availability to these injectable treatments.
Per estimates, more than two billion are projected to be obese by 2030 if no action is taken.
"Our latest guidelines affirms that excess weight is a chronic disease that can be treated with thorough and lifelong care," remarked WHO director-general Tedros Adhanom Ghebreyesus.
High costs, constrained manufacturing, and logistical bottlenecks are key hurdles to universal access to the treatments that can help people shift substantial body mass, notes the body.
Skinny Jab Scarcity
Even under the present most favorable case, the manufacturing of such drugs could only cover approximately 100 million people – under 10% of those who need them, per the health organization.
The advice encourages countries and companies to expand access, by approaches like patent sharing.
A patent on a key compound – the core ingredient of a leading brand – is scheduled to end in a number of countries in 2026.
How Weight-Loss Injections Work
GLP-1 drugs imitate a biological compound to slow digestion, reduce hunger and increase feelings of fullness so people reduce food intake.
Patients commonly begin shedding pounds in the initial weeks of beginning the weekly injections.
Studies points to users may regain a significant portion a year later of discontinuing the medication, as their typical appetite resume.
Being above a healthy weight elevates your likelihood for contracting health problems, such as diabetes, cardiovascular issues, stroke, and some cancers.
Excess weight affects individuals in all nations and was responsible for over three and a half million deaths worldwide in 2024, per the WHO.
